Impact of stratifin/14-3-3σ on survival and interstitial lung disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
SFN levels in plasma were associated with therapeutic efficacy and ICI-ILD pattern in patients with NSCLC receiving cancer immunotherapy. SFN can be a diagnostic biomarker for ICI-ILD with DAD patterns as well as a prognostic biomarker for cancer immunotherapy.
Authors
- Yoshiaki Zaizen (ORCID: https://orcid.org/0000-0003-2274-4599)
- Kenta Murotani (ORCID: https://orcid.org/0000-0003-0623-9365)
- Tomoaki Hoshino (ORCID: https://orcid.org/0000-0002-0459-4913)
- Koichi Azuma
- Daiki Murata (ORCID: https://orcid.org/0000-0002-4295-5046)
Institutions
- Kurume University (JP)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-07-05
- DOI
- https://doi.org/10.1007/s00262-025-04093-1
- Primary Topic
- 14-3-3 protein interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development